Cyclacel Pharmaceuticals (NASDAQ:BGMS – Get Free Report) and MSC Industrial Direct (NYSE:MSM – Get Free Report) are both industrials companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.
Risk and Volatility
Cyclacel Pharmaceuticals has a beta of -0.44, suggesting that its stock price is 144% less volatile than the S&P 500. Comparatively, MSC Industrial Direct has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500.
Profitability
This table compares Cyclacel Pharmaceuticals and MSC Industrial Direct’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cyclacel Pharmaceuticals | -118.27% | -31.60% | -27.72% |
| MSC Industrial Direct | 5.55% | 18.72% | 10.57% |
Analyst Recommendations
This is a summary of current ratings and recommmendations for Cyclacel Pharmaceuticals and MSC Industrial Direct, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cyclacel Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
| MSC Industrial Direct | 0 | 2 | 7 | 1 | 2.90 |
MSC Industrial Direct has a consensus target price of $133.22, indicating a potential upside of 11.51%. Given MSC Industrial Direct’s stronger consensus rating and higher probable upside, analysts clearly believe MSC Industrial Direct is more favorable than Cyclacel Pharmaceuticals.
Valuation and Earnings
This table compares Cyclacel Pharmaceuticals and MSC Industrial Direct”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cyclacel Pharmaceuticals | $750,000.00 | 7.07 | -$3.00 million | ($3.64) | -0.22 |
| MSC Industrial Direct | $4.01 billion | 1.66 | $222.59 million | $3.98 | 30.02 |
MSC Industrial Direct has higher revenue and earnings than Cyclacel Pharmaceuticals. Cyclacel Pharmaceuticals is trading at a lower price-to-earnings ratio than MSC Industrial Direct, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. Comparatively, 79.3% of MSC Industrial Direct shares are held by institutional investors. 23.7% of Cyclacel Pharmaceuticals shares are held by insiders. Comparatively, 19.0% of MSC Industrial Direct shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
MSC Industrial Direct beats Cyclacel Pharmaceuticals on 12 of the 14 factors compared between the two stocks.
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for the treatment of cancer. Its research programs are designed to target key proteins involved in tumor-cell growth, division and survival, with the goal of addressing cancers that have limited treatment options. The company’s pipeline has included fadraciclib (CYC065), an investigational selective cyclin-dependent kinase 2 inhibitor, and sapacitabine (CYC682), an oral nucleoside analog studied in several oncology indications.
About MSC Industrial Direct
MSC Industrial Direct is a North American distributor of metalworking products and maintenance, repair and operations (MRO) supplies. The company serves manufacturers and other industrial customers, offering products such as cutting tools, abrasives, hand tools, safety equipment, fasteners and electrical supplies. In addition to product distribution, MSC provides services designed to help customers manage purchasing and inventory. These include online ordering, inventory-management programs, vending solutions and technical support for metalworking and manufacturing applications.
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
